Evidence map›Paper›PMID 33515206›Full record

ArticleInfectious diseases and therapy2021

Interim Effectiveness and Safety Comparison of Bedaquiline-Containing Regimens for Treatment of Diabetic Versus Non-Diabetic MDR/XDR-TB Patients in China: A Multicenter Retrospective Cohort Study.

Li Shi, Jingtao Gao, Mengqiu Gao, Ping Deng, Shu Chen, Minfu He, Wenjun Feng, Xiaoyun Yang, Yunhui Huang, Fang He and 14 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Infectious diseases and therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 2 pooled it
1.7field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 29 citations in OpenAlex.

  1. Pooled it
  2. Bedaquiline-containing regimens and multidrug-resistant tuberculosis: a systematic review and meta-analysis.Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia · 2022
    Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Clinical standards for the dosing and management of TB drugs.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2022
    Article
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 10 institutions in 1 country.

Li ShiDepartment of Tuberculosis, Changsha Central Hospital, University of South China, Changsha, 410007, China.
Jingtao GaoClinical Center on TB, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, 101149, China.
Mengqiu GaoDepartment of Tuberculosis, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, 101149, China.
Ping DengDepartment of Tuberculosis, Changsha Central Hospital, University of South China, Changsha, 410007, China.
Shu ChenBeijing Innovation Alliance of TB Diagnosis and Treatment, Beijing, 101149, China.
Minfu HeBeijing Innovation Alliance of TB Diagnosis and Treatment, Beijing, 101149, China.
Wenjun FengDepartment of Tuberculosis, Changsha Central Hospital, University of South China, Changsha, 410007, China.
Xiaoyun YangDepartment of Tuberculosis, Changsha Central Hospital, University of South China, Changsha, 410007, China.
Yunhui HuangDepartment of Tuberculosis, Changsha Central Hospital, University of South China, Changsha, 410007, China.
Fang HeDepartment of Tuberculosis, Changsha Central Hospital, University of South China, Changsha, 410007, China.
Yumeng HuDepartment of Tuberculosis, Changsha Central Hospital, University of South China, Changsha, 410007, China.
Liping LeiDepartment of Tuberculosis, Changsha Central Hospital, University of South China, Changsha, 410007, China.
Xuelian LiDepartment of Tuberculosis, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, 101149, China.
Juan DuDepartment of Tuberculosis, Wuhan Pulmonary Hospital, Wuhan, 430030, China.
Xiaomeng HuDepartment of Tuberculosis, Wuhan Pulmonary Hospital, Wuhan, 430030, China.
Zhi LiuDepartment of Tuberculosis, Shenzhen Third People's Hospital, Shenzhen, 518000, China.
Peijun TangThe Fifth People's Hospital of Suzhou, Suzhou, 215000, China.
Junfeng HanTianjin Haihe Hospital, Tianjin, 300000, China.
Hua WangAnhui Chest Hospital, Hefei, 230000, China.
Yi HanAnhui Chest Hospital, Hefei, 230000, China.
Wei ShuClinical Center on TB, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, 101149, China.
Yuxian SunClinical Center on TB, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, 101149, China.
Yi PeiDepartment of Tuberculosis, Changsha Central Hospital, University of South China, Changsha, 410007, China. 1113284116@qq.com.
Yuhong LiuClinical Center on TB, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, 101149, China. liuyuhong0516@126.com.
Changsha Central Hospital · CNBeijing Chest Hospital · CNUniversity of South China · CNBeijing Advanced Sciences and Innovation Center · CNCapital Medical University · CNWuhan Pulmonary Hospital · CNXi'an Chest Hospital · CNShenzhen Third People’s Hospital · CNThe Fifth People’s Hospital of Suzhou · CNTianjin haihe hospital · CN

Funding

Hunan Administration of Traditional Chinese Medicine 201890Science and technology bureau Project of Changsha 2018-kq1801145Scientific research project of Hunan provincial health commission 20201439
6 · The paper itself

Abstract

introductionDiabetes mellitus (DM), a common tuberculosis (TB) comorbidity, is associated with delayed bacillary clearance during anti-TB treatment and unfavorable outcomes. Bedaquiline (BDQ), when used as part of multidrug regimen for multidrug-resistant/extensively drug-resistant tuberculosis (MDR/XDR-TB), has been shown to be effective and safe although treatment outcome and risks for patients with MDR/XDR-TB and DM are unknown. A multicenter retrospective study was conducted to compared the safety and effectiveness of 24-week BDQ-containing anti-TB treatment for patients with MDR/XDR-TB with and without DM.

methodsThe study of patients with MDR/XDR-TB with or without DM (enrolled February 2018-September 2019, 21 Chinese hospitals) was supervised by the New Drug Introduction and Protection Program (NDIP). Of 640 patients with MDR/XDR-TB receiving BDQ-containing anti-TB treatments, two propensity score-matched groups (107 DM/107 non-DM) were compared for cumulative culture conversion rate, time to culture conversion, adverse events, and corrected QT interval.

resultsBody mass index was higher in patients with DM than patients without DM (23.29 ± 3.9 vs. 20.5 ± 3.6, P < 0.001); lung cavity prevalence (86.9% vs. 72.9%, P = 0.037) was also higher in patients with DM; the non-DM group had higher hepatitis prevalence (29.0% vs. 15.9%, P = 0.022). No significant intergroup differences were found for sputum culture conversion rate at week 8 (80.0% vs. 81.4%, P = 0.884), at week 24 (95.6% vs. 98.2%, P = 0.629), or for median time to sputum culture conversion [56 days (IQR 28-63) vs. 56 days (IQR 28-84) (P = 0.687)]. Favorable post-24-week treatment outcomes were presented by 90.7% and 93.5% in the DM group and non-DM group, respectively, without significant intergroup differences (P = 0.448). The DM adverse event rate exceeded non-DM rate (77.6% vs. 64.5%, P = 0.035).

conclusionDespite some differences in baseline characteristics, Chinese patients with MDR/XDR-TB with or without DM had similar sputum culture conversion rates and favorable treatment outcomes post-24-week BDQ-containing anti-TB treatment. Low BMI but not DM is risk factor associated with unfavorable outcome of patients with MDR/XDR-TB.

Indexed as

Adverse eventBedaquilineDiabetesMultidrug resistantTuberculosis

Identifiers

PMID33515206
PMCPMC7954881
OpenAlexW3123210133

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.